Schizophrenia Research Forum - A Catalyst for Creative Thinking
Home Profile Membership/Get Newsletter Log In Contact Us
 For Patients & Families
What's New
Recent Updates
SRF Papers
Current Papers
Search All Papers
Search Comments
Research News
Conference News
Plain English
Current Hypotheses
Idea Lab
Online Discussions
Virtual Conferences
What We Know
Animal Models
Drugs in Trials
Research Tools
Community Calendar
General Information
Member Directory
Researcher Profiles
Institutes and Labs
About the Site
SRF Team
Advisory Board
Support Us
How to Cite
Fan (E)Mail
The Schizophrenia Research Forum web site is sponsored by the Brain and Behavior Research Foundation and was created with funding from the U.S. National Institute of Mental Health.
Online Discussions

Updated 14 November 2012
Printable version

Live Discussion: Neurotropic Infectious Agents and Cognitive Impairment in Schizophrenia

Vishwajit Nimgaonkar

Mikhail Pletnikov

Konasale Prasad

Robert Yolken

On Tuesday, 13 November 2012, SRF held another installment in our Schizophrenia Bulletin theme section Webinar series to learn about and discuss this topic.

Thanks to the Maryland Psychiatric Research Center and Oxford Press, publishers of Schizophrenia Bulletin, for kindly providing open access to the introductory article for this Webinar.

Listen to the Webinar

Vishwajit Nimgaonkar's Presentation

Mikhail Pletnikov's Presentation

Konasale Prasad's Presentation

Robert Yolken's Presentation

View Comments By:
Georg Winterer — Posted 30 October 2012
Chris Carter — Posted 4 November 2012

Background Text
by Michele Solis

Infectious agents like the human habitat well enough, and some even prefer our nervous systems. As researchers debate whether infections contribute to schizophrenia risk, some scientists are beginning to ask whether infectious agents can also alter mental processes in people already diagnosed with schizophrenia.

Robert Yolken of Johns Hopkins University provided an overview of this “epidiagnostic” idea, which sees the vagaries of infection as possible modulators of processes such as cognitive functions among patients.

Researchers are now specifically exploring whether the cognitive impairments in schizophrenia are modified by infections with herpes simplex virus 1 (HSV1) and the parasite Toxoplasma gondii. Konasale Prasad of the University of Pittsburgh described work on HSV1, which, once it infects a person, remains in the nervous system throughout life, alternating between dormant and active states. HSV1-exposed people with schizophrenia exhibit worse cognitive symptoms in the realms of working memory, verbal memory, and executive function compared with unexposed patients with schizophrenia. Preliminary experiments now suggest that treatment with anti-herpes medications can improve these impairments. Importantly, even people without schizophrenia perform less well on specific cognitive tasks if they have been exposed to HSV1. Because the integrity of the immune system could modulate vulnerability to infection in the first place, Vishwajit Nimgaonkar of the University of Pittsburgh discussed potential interactions between infection and host genetic variation at the major histocompatibility complex (MHC) locus, a region containing immune-related genes that has been implicated in schizophrenia. This has offered up a potential interaction between a common variant in the region and HSV1 exposure on schizophrenia risk, and further studies are needed.

Toxoplasma gondii, a notorious resident of cats' litter boxes, may instigate cognitive deficits in humans upon infecting their nervous systems. Animal models of T. gondii infection have been developed to study this process in detail, and Mikhail Pletnikov of Johns Hopkins University discussed work in rodents infected with the parasite. These show impairments in spatial learning and memory analogous to impairments found in schizophrenia. Exploring these diverse questions may open up some novel avenues for treatment of cognitive impairments and provide some insight into the epidemiological hints of roles for infection in schizophrenia.

Comments on Online Discussion
Comment by:  Georg Winterer (Disclosure)
Submitted 29 October 2012 Posted 30 October 2012

Great topic! Myself, I have recently started to think...  Read more

View all comments by Georg Winterer

Comment by:  Chris Carter
Submitted 1 November 2012 Posted 4 November 2012

This Webinar group has made an enormous contribution...  Read more

View all comments by Chris Carter
Submit a Comment on This Online Discussion
Make a comment on this live discussion. 

If you already are a member, please login.
Not sure if you are a member? Search our member database.

*First Name  
*Last Name  
Country or Territory  
*Login Email Address  
*Confirm Email Address  
*Confirm Password  
Remember my Login and Password?  
Get SRF newsletter with recent commentary?  
Enter the code as it is shown below:
This code helps prevent automated registrations.

Please note: A member needs to be both registered and logged in to submit a comment.


(If coauthors exist for this comment, please enter their names and email addresses at the end of the comment.)


SRF News
SRF Comments
Text Size
Reset Text Size
Live Discussion FAQs

Webinar: A Webinar is a seminar conducted remotely over the Web. Attendees view the slides through their Web browser and hear the presentations over their own telephones.

Registration: All participants are to register by clicking on the "Register for the Webinar" link.

Access: After you register, you will receive an e-mail with a link to the Webinar and a phone number.
New Schizophrenia Fact Sheet for Patients and Families

Latest BBRF Research Breakthroughs

Visit our Facebook page and our Blog.

Support the Brain & Behavior Research Foundation Today.

Research Participants
Copyright © 2005- 2016 Schizophrenia Research Forum Privacy Policy Disclaimer Disclosure Copyright